Whalesbook
📉 The Financial Deep Dive
Dr. Agarwal's Health Care Limited has posted a commendable financial performance for the quarter and nine months ended December 31, 2025. The company demonstrated significant year-on-year (YoY) growth across key metrics on a consolidated basis.
The Numbers:
- Consolidated Q3 FY2026: Total income surged by 21.8% YoY to INR 540 Crores, with revenue from operations growing 23.0% YoY to INR 530 Crores. EBITDA reached INR 155 Crores, marking a 21.3% YoY increase, while maintaining healthy EBITDA margins at 28.6%. Profit After Tax (PAT) saw an impressive 54.5% YoY jump to INR 44 Crores, resulting in PAT margins of 8.1%.
- Consolidated 9M FY2026: For the nine-month period, total income grew 20.8% YoY to INR 1,548 Crores, and revenue from operations increased 21.2% YoY to INR 1,516 Crores. EBITDA rose 23.6% YoY to INR 440 Crores (EBITDA margins: 28.4%), with PAT skyrocketing 74.3% YoY to INR 118 Crores (PAT margins: 7.6%).
- Standalone Q3 FY2026: Revenue from operations grew 25.0% YoY to INR 334.84 Crores, and PAT saw a substantial 84.5% YoY increase to INR 14.06 Crores.
- Standalone 9M FY2026: Revenue from operations was up 23.9% YoY to INR 945.53 Crores, and PAT witnessed an extraordinary 347.5% YoY surge to INR 45.55 Crores.
The Quality:
The standout performance is the significant acceleration in PAT growth, particularly on a standalone basis for the nine-month period. The 347.5% YoY PAT increase indicates robust operational leverage and efficient cost management, significantly outpacing revenue growth. Consolidated EBITDA margins have been maintained at strong levels, reflecting sustained operational efficiency and disciplined cost controls. While specific details on balance sheet or cash flow drivers were not the focus of this announcement, the strong profit trajectory is a positive indicator.
The Grill:
Management commentary, led by CEO Dr. Adil Agarwal, expressed high confidence in achieving the company's annual guidance. This optimism is rooted in sustained execution, strong patient volumes, the performance of mature centers, and effective cost management strategies. The focus remains on accelerating organic growth through aggressive greenfield expansion and deepening market presence. No specific concerns or analyst queries were highlighted in the provided update.
🚩 Risks & Outlook
The outlook for Dr. Agarwal's Health Care is optimistic, driven by a clear strategy to expand organically via greenfield projects and enhance market penetration. The company intends to leverage its established brand strength and scalable operational model for sustainable long-term growth, while upholding high clinical quality standards.
Key corporate developments further bolster this outlook:
- Ethiopia Expansion: Incorporation of a wholly-owned subsidiary, 'Orbit Healthcare Services (Mauritius) Limited,' in Ethiopia, with an initial investment of USD 200,000, signals international growth ambitions.
- Aditya Jyot Acquisition: The company acquired additional shares, making Aditya Jyot Eye Hospital Private Limited a wholly-owned subsidiary through an investment of INR 6.25 Crores, strengthening its specialized service offerings.
- Associate Status Change: The proposed termination of the Shareholders Agreement for Idearx Services Private Limited means it will cease to be an associate company, though Dr. Agarwal's Health Care will retain its 14.54% equity stake.
- Office Relocation: The registered and corporate office is set to move within Chennai effective February 5, 2026, aimed at improving administrative efficiency.
Investors should closely monitor the successful execution of greenfield expansion plans and the strategic integration of acquired entities. The company's ability to maintain its growth momentum and profitability amidst market dynamics will be key.